PT4180519T - Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados - Google Patents
Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionadosInfo
- Publication number
- PT4180519T PT4180519T PT221974447T PT22197444T PT4180519T PT 4180519 T PT4180519 T PT 4180519T PT 221974447 T PT221974447 T PT 221974447T PT 22197444 T PT22197444 T PT 22197444T PT 4180519 T PT4180519 T PT 4180519T
- Authority
- PT
- Portugal
- Prior art keywords
- cell
- transgenic
- antigen receptor
- chimeric antigen
- related methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323623P | 2016-04-15 | 2016-04-15 | |
| US201662323675P | 2016-04-16 | 2016-04-16 | |
| US201762461677P | 2017-02-21 | 2017-02-21 | |
| US201762462243P | 2017-02-22 | 2017-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4180519T true PT4180519T (pt) | 2025-09-04 |
Family
ID=59285314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177356706T PT3443075T (pt) | 2016-04-15 | 2017-04-14 | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
| PT221974447T PT4180519T (pt) | 2016-04-15 | 2017-04-14 | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177356706T PT3443075T (pt) | 2016-04-15 | 2017-04-14 | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377637B2 (OSRAM) |
| EP (3) | EP3443075B1 (OSRAM) |
| JP (1) | JP7058223B2 (OSRAM) |
| KR (3) | KR20240000616A (OSRAM) |
| CN (1) | CN109790517B (OSRAM) |
| AU (1) | AU2017250769B2 (OSRAM) |
| BR (1) | BR112018071199A2 (OSRAM) |
| ES (2) | ES2933961T3 (OSRAM) |
| PT (2) | PT3443075T (OSRAM) |
| SG (1) | SG11201808831TA (OSRAM) |
| WO (1) | WO2017180989A2 (OSRAM) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202101358XA (en) | 2015-01-26 | 2021-03-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2989858A1 (en) * | 2015-06-17 | 2016-12-22 | The Uab Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| US11643668B2 (en) | 2015-06-17 | 2023-05-09 | The Uab Research Foundation | CRISPR/Cas9 complex for genomic editing |
| US10799535B2 (en) | 2015-10-05 | 2020-10-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| ES2953925T3 (es) * | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
| US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2019510503A (ja) * | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| ES2933961T3 (es) | 2016-04-15 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados |
| BR112019007715A2 (pt) * | 2016-10-19 | 2019-07-09 | Cellectis Sa | inserção vetorizada de genes para terapia aprimorada com células imunes |
| GB2573664B (en) * | 2016-10-27 | 2022-09-28 | Intima Bioscience Inc | Viral methods of T cell therapy |
| EP3606550A2 (en) | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3638317A4 (en) | 2017-06-15 | 2021-03-17 | The Regents of The University of California | TARGETED NONVIRAL DNA INSERTIONS |
| US11053484B2 (en) | 2017-06-30 | 2021-07-06 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| AU2018308923A1 (en) * | 2017-07-26 | 2020-03-12 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (CAR) immune cell selection |
| KR102770787B1 (ko) | 2017-10-27 | 2025-02-19 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| BR112020016138A2 (pt) * | 2018-02-11 | 2020-12-15 | Memorial Sloan-Kettering Cancer Center | Receptores de células t não restritos ao hla e usos dos mesmos |
| SG11202007513PA (en) * | 2018-02-16 | 2020-09-29 | Kite Pharma Inc | Modified pluripotent stem cells and methods of making and use |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| WO2019199689A1 (en) * | 2018-04-09 | 2019-10-17 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising a viral vector for expression of a transgene and an effector |
| IL304025A (en) | 2018-04-12 | 2023-08-01 | Prec Biosciences Inc | Optimized engineered nucleases with specificity for the human T cell receptor alpha constant region gene |
| WO2019204397A1 (en) * | 2018-04-17 | 2019-10-24 | Wake Forest University Health Sciences | Methods and compositions for th9 cell mediated cancer treatment |
| WO2019226998A1 (en) * | 2018-05-25 | 2019-11-28 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| US20200054675A1 (en) | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| US12246067B2 (en) | 2018-06-19 | 2025-03-11 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| JP2021529559A (ja) * | 2018-07-03 | 2021-11-04 | ソティオ，リミティド ライアビリティ カンパニー | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
| US20210381008A1 (en) * | 2018-07-26 | 2021-12-09 | Kyoto University | Method for producing foreign antigen receptor gene-introduced cell |
| NZ772146A (en) | 2018-08-14 | 2025-08-29 | Sotio Llc | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| CN120025452A (zh) | 2018-12-12 | 2025-05-23 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| EP3898946B1 (en) * | 2018-12-19 | 2023-02-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| WO2020160489A1 (en) * | 2019-02-01 | 2020-08-06 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| JP7650809B2 (ja) * | 2019-03-06 | 2025-03-25 | レンティジェン・テクノロジー・インコーポレイテッド | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
| AU2020253023B2 (en) | 2019-03-29 | 2022-07-14 | F. Hoffmann-La Roche Ag | Method for the generation of an FcRn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3135224A1 (en) * | 2019-04-11 | 2020-10-15 | Fate Therapeutics, Inc. | Cd3 reconstitution in engineered ipsc and immune effector cells |
| JP7754722B2 (ja) | 2019-05-01 | 2025-10-15 | ジュノー セラピューティクス インコーポレイテッド | 改変されたｃｄ２４７遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法 |
| JP2022533128A (ja) * | 2019-05-16 | 2022-07-21 | ユニバーシティ オブ ワシントン | Ｃａｒ ｔ細胞のｌｏｃｋｒ媒介性動員 |
| MX2021015540A (es) * | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| CN115298208A (zh) | 2019-07-19 | 2022-11-04 | 纪念斯隆-凯特琳癌症中心 | 免疫治疗用融合多肽 |
| EP4003407A1 (en) | 2019-07-23 | 2022-06-01 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN117925528A (zh) * | 2019-07-24 | 2024-04-26 | 浙江煦顼技术有限公司 | 具有增强记忆t细胞表型的修饰t细胞 |
| CA3151690A1 (en) * | 2019-09-23 | 2021-04-01 | Beau WEBBER | Genetically-edited immune cells and methods of therapy |
| WO2021061946A2 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | A promoter specific for non-pigmented ciliary epithelial cells |
| SG10201909544YA (en) * | 2019-10-11 | 2021-05-28 | Nat Univ Singapore | Genetically Modified T Cells And Uses Thereof |
| MX2022005817A (es) * | 2019-11-13 | 2022-06-08 | Crispr Therapeutics Ag | Metodos de fabricacion de linfocitos t-car. |
| BR112022009152A2 (pt) * | 2019-11-13 | 2022-07-26 | Crispr Therapeutics Ag | Processo de fabricação para preparar células t expressando receptores de antígenos quiméricos |
| CN113122576A (zh) * | 2019-12-31 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种通用型truck-t细胞、其制备方法以及用途 |
| JP2023510238A (ja) * | 2020-01-02 | 2023-03-13 | エディティ セラピューティクス リミテッド | 送達組成物および方法 |
| CA3171369A1 (en) * | 2020-02-28 | 2021-09-02 | Wisconsin Alumni Research Foundation | Nonviral generation of genome edited chimeric antigen receptor t cells |
| EP4121453A2 (en) * | 2020-03-20 | 2023-01-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
| AU2021300112A1 (en) * | 2020-06-29 | 2023-02-16 | Cell Medica, Inc. | Methods and compositions for the reduction of chimeric antigen receptor tonic signaling |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| CN116096864A (zh) | 2020-07-30 | 2023-05-09 | 居里研究所 | Socs1缺陷的免疫细胞 |
| CN116323920A (zh) * | 2020-08-07 | 2023-06-23 | 荷兰商新基因治疗公司 | 富集基因工程t细胞的方法 |
| US20230364137A1 (en) * | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Chimeric antigen receptor expression systems |
| CA3200741A1 (en) * | 2020-12-01 | 2022-06-09 | Daniel Zurr | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| EP4019538A1 (en) * | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes |
| IL305804A (en) | 2021-03-11 | 2023-11-01 | Inst Curie | Transmembrane neoantigenic peptides |
| JP2024510981A (ja) | 2021-03-11 | 2024-03-12 | ムネモ・セラピューティクス | 腫瘍ネオ抗原ペプチド及びその使用 |
| IL305810A (en) | 2021-03-11 | 2023-11-01 | Mnemo Therapeutics | Tumor neoantigenic peptides |
| JP2024517968A (ja) * | 2021-05-14 | 2024-04-23 | アピア バイオ， インコーポレイテッド | 幹細胞からの操作されたｔ細胞の産生 |
| WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
| CN118871572A (zh) * | 2021-10-14 | 2024-10-29 | 阿彼雅生物有限公司 | 使用多种t细胞受体对干细胞t细胞进行工程化 |
| US20250000907A1 (en) * | 2021-11-22 | 2025-01-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineered immune cells with reduced sirt6 expression |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| US20250115916A1 (en) | 2022-01-21 | 2025-04-10 | Mnemo Therapeutics | Modulation of suv39h1 expression by rnas |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| WO2023178227A2 (en) * | 2022-03-17 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Chimeric lactate receptor engineered t cells |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024039576A2 (en) | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| WO2024050551A2 (en) * | 2022-09-02 | 2024-03-07 | Oncosenx, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
| BE1031219B1 (fr) | 2022-12-28 | 2024-07-29 | Quidditas Sa | Composition, cellules immunitaires la comprenant et utilisation de ces dernières |
| WO2025096560A1 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025096594A2 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025213167A1 (en) * | 2024-04-05 | 2025-10-09 | Roswell Park Cancer Institute Corporation | Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| DE60106469T2 (de) | 2001-12-22 | 2005-10-13 | 4-Antbody AG | Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen |
| CN100360565C (zh) | 2001-12-22 | 2008-01-09 | 4-抗体股份公司 | 制备脊椎动物淋巴细胞和生产结合蛋白的方法 |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005026718A1 (en) | 2003-08-28 | 2005-03-24 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| US9051391B2 (en) | 2007-06-11 | 2015-06-09 | Takara Bio Inc. | Method for expression of specific gene |
| ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| AU2010275432A1 (en) | 2009-07-24 | 2012-02-02 | Sigma-Aldrich Co. Llc. | Method for genome editing |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| HRP20190556T1 (hr) | 2009-11-03 | 2019-06-14 | City Of Hope | SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| ES2828663T3 (es) | 2012-04-18 | 2021-05-27 | Univ Leland Stanford Junior | Dirección genética no disruptiva |
| CN111676196A (zh) | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| MY189533A (en) | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR102332790B1 (ko) | 2013-02-15 | 2021-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス， インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊 |
| CA3185368A1 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t cells derived from pluripotent stem cells |
| CA2909701C (en) | 2013-04-17 | 2022-12-06 | Baylor College Of Medicine | Immunosuppressive tgf-.beta. signal converter |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| EP3309248B1 (en) | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| AU2015233347A1 (en) | 2014-03-21 | 2016-09-08 | Cellectis | Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS) |
| CN106459918A (zh) | 2014-04-24 | 2017-02-22 | 得克萨斯州大学系统董事会 | 施加诱导多能干细胞产生过继细胞疗法产品 |
| WO2015172147A1 (en) | 2014-05-09 | 2015-11-12 | Research Foundation Of The City University Of New York | Tcr(alpha)-lcr-derived gene regulatory cassettes |
| WO2015188065A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
| JP6688231B2 (ja) | 2014-06-06 | 2020-04-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的遺伝子座を修飾するための方法及び組成物 |
| RU2017113134A (ru) | 2014-09-19 | 2018-10-19 | Регенерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы |
| WO2016081924A1 (en) | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| WO2016166268A1 (en) | 2015-04-17 | 2016-10-20 | Cellectis | Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes |
| KR102012119B1 (ko) * | 2015-05-15 | 2019-08-19 | 오루 카약 인코포레이티드 | 큰 조종석을 갖는 접이식 카약 |
| AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US10799535B2 (en) * | 2015-10-05 | 2020-10-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| ES2953925T3 (es) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| EP3426690A4 (en) | 2016-03-11 | 2019-10-09 | Bluebird Bio, Inc. | GENOMEDITIZED IMMUNEFFECTOR CELLS |
| EP3430136A2 (en) | 2016-03-19 | 2019-01-23 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| JP2019510503A (ja) | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| ES2933961T3 (es) | 2016-04-15 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados |
-
2017
- 2017-04-14 ES ES17735670T patent/ES2933961T3/es active Active
- 2017-04-14 KR KR1020237042980A patent/KR20240000616A/ko active Pending
- 2017-04-14 PT PT177356706T patent/PT3443075T/pt unknown
- 2017-04-14 KR KR1020187032919A patent/KR102437015B1/ko active Active
- 2017-04-14 EP EP17735670.6A patent/EP3443075B1/en active Active
- 2017-04-14 WO PCT/US2017/027601 patent/WO2017180989A2/en not_active Ceased
- 2017-04-14 BR BR112018071199-3A patent/BR112018071199A2/pt active Search and Examination
- 2017-04-14 EP EP22197444.7A patent/EP4180519B1/en active Active
- 2017-04-14 SG SG11201808831TA patent/SG11201808831TA/en unknown
- 2017-04-14 US US16/091,494 patent/US11377637B2/en active Active
- 2017-04-14 AU AU2017250769A patent/AU2017250769B2/en active Active
- 2017-04-14 JP JP2018554069A patent/JP7058223B2/ja active Active
- 2017-04-14 CN CN201780037351.1A patent/CN109790517B/zh active Active
- 2017-04-14 PT PT221974447T patent/PT4180519T/pt unknown
- 2017-04-14 ES ES22197444T patent/ES3039670T3/es active Active
- 2017-04-14 EP EP25181439.8A patent/EP4628587A2/en active Pending
- 2017-04-14 KR KR1020227029151A patent/KR102614675B1/ko active Active
-
2022
- 2022-05-25 US US17/824,650 patent/US12404316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3443075T (pt) | 2022-12-16 |
| EP3443075A2 (en) | 2019-02-20 |
| WO2017180989A2 (en) | 2017-10-19 |
| AU2017250769A1 (en) | 2018-11-01 |
| KR102437015B1 (ko) | 2022-08-29 |
| BR112018071199A2 (pt) | 2019-02-12 |
| SG11201808831TA (en) | 2018-11-29 |
| EP4180519B1 (en) | 2025-06-11 |
| WO2017180989A3 (en) | 2017-12-14 |
| ES2933961T3 (es) | 2023-02-15 |
| US20220411753A1 (en) | 2022-12-29 |
| AU2017250769B2 (en) | 2022-07-14 |
| EP3443075B1 (en) | 2022-09-28 |
| EP4180519A1 (en) | 2023-05-17 |
| CN109790517A (zh) | 2019-05-21 |
| CN109790517B (zh) | 2023-05-02 |
| US12404316B2 (en) | 2025-09-02 |
| EP4628587A2 (en) | 2025-10-08 |
| KR20220123325A (ko) | 2022-09-06 |
| JP2019511236A (ja) | 2019-04-25 |
| US20190119638A1 (en) | 2019-04-25 |
| KR102614675B1 (ko) | 2023-12-19 |
| KR20180133496A (ko) | 2018-12-14 |
| CA3020923A1 (en) | 2017-10-19 |
| ES3039670T3 (en) | 2025-10-23 |
| JP7058223B2 (ja) | 2022-04-21 |
| US11377637B2 (en) | 2022-07-05 |
| KR20240000616A (ko) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3443075T (pt) | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados | |
| IL273956A (en) | Methods for preparing cells expressing chimeric antigen receptor | |
| IL263626A (en) | Chimeric antigen receptors and methods of use | |
| PL3294764T3 (pl) | Kompozycje chimerycznego receptora antygenowego | |
| IL254254A0 (en) | chimeric antigen receptor | |
| SG10202012157QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| DK3166968T3 (da) | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler | |
| SG11201802895QA (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| PT3674315T (pt) | Recetores de antigénios quiméricos, composições e métodos | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| SG11201808411RA (en) | Chimeric antigen and t cell receptors and methods of use | |
| SG11201606790XA (en) | Chimeric antigen receptor | |
| GB201607968D0 (en) | Chimeric antigen receptor | |
| SG11201705293WA (en) | Methods of making chimeric antigen receptor-expressing cells | |
| GB201610512D0 (en) | Chimeric antigen receptor | |
| SG11201701297WA (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| SG11201800872QA (en) | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| IL266950B1 (en) | γδ t cells expressing a chimeric antigen receptor for use in immunotherapy | |
| GB201519900D0 (en) | Chimeric antigen receptor | |
| GB201721421D0 (en) | Chimeric antigen receptor | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| HK40004398A (en) | Chimeric antigen receptor t cell compositions | |
| GB201612844D0 (en) | Chimeric antigen receptor |